Company / Cash & Equivalents
Organon & Co. Cash & Equivalents History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$574.0M
FY2025
5-year range
$574.0M / $737.0M
FY2021-FY2025
Trend
-15.0%
vs FY2024
Sector context
#35 of 207
Health Care
What the data says
Organon & Co.'s cash & equivalents of $574M is higher than 83% of companies in the Health Care sector (FY2025). Cash & Equivalents has declined for 4 consecutive years, from $737M in FY2021 to $574M in FY2025.
Based on SEC 10-K filings.
$574M in FY2025 with a 5-year CAGR of +116.7%. Top quartile in the Health Care sector.
Declined from $693M to $574M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -6.7%
- 5-Year CAGR
- +116.7%
- 10-Year CAGR
- -
Sector benchmark
-14.3% below sector average
Key checks
Key Insights
- Organon & Co.'s cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of +116.7%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 15.0% year-over-year.
- Ranks #35 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $574.0M | -15.0% |
| FY2024 | $675.0M | -2.6% |
| FY2023 | $693.0M | -1.8% |
| FY2022 | $706.0M | -4.2% |
| FY2021 | $737.0M | +6041.7% |
| FY2020 | $12.0M | - |
| FY2019 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026